Deals

BioMarin Licenses HM15421/GC1134A Subcutaneous Fabry Disease Enzyme Therapy from GC Biopharma and Hanmi in USD 110 Million Deal
BioMarin PharmaceuticalNASDAQ: BMRN

BioMarin Licenses HM15421/GC1134A Subcutaneous Fabry Disease Enzyme Therapy from GC Biopharma and Hanmi in USD 110 Million Deal

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced that it has entered into an exclusive worldwide (excluding Korea) license agreement with GC Biopharma Corp. and Hanmi Pharm Co., Ltd. to co‑develop and…

Sino Biopharmaceutical's CTTQ Partners with Revvity to Launch X‑Lab Joint Shared Laboratory for Antibody Drug R&D

Sino Biopharmaceutical’s CTTQ Partners with Revvity to Launch X‑Lab Joint Shared Laboratory for Antibody Drug R&D

Shanghai Pharmaceuticals Renews Sales and Distribution Agreement with Fudan‑Zhangjiang Through 2029 Under RMB 272 Million Caps

Shanghai Pharmaceuticals Renews Sales and Distribution Agreement with Fudan‑Zhangjiang Through 2029 Under RMB 272 Million Caps

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
HBM BMS Multi-Specific Antibody Deal Targets $1 Billion Milestones
BMSBristol-Myers Squibb

HBM BMS Multi-Specific Antibody Deal Targets $1 Billion Milestones

Sanofi Adel Alzheimer's Deal Targets Phase 1 ADEL-Y01 Antibody
AdelSanofi

Sanofi Adel Alzheimer’s Deal Targets Phase 1 ADEL-Y01 Antibody

Byterna Therapeutics Raises Angel Plus Round for cmRNA CAR‑T Pipeline
Byterna TherapeuticsCAR-T

Byterna Therapeutics Raises Angel Plus Round for cmRNA CAR‑T Pipeline

Kelun-Biotech Settles with Medilink in Multi-Million Dollar ADC Revenue Sharing Deal
ADC / XDCHKG: 6990

Kelun-Biotech Settles with Medilink in Multi-Million Dollar ADC Revenue Sharing Deal

Show More